Mithra annonce les premiers résultats positifs pour l’étude de phase III du contraceptif oral Estelle® aux États-Unis/Canada

30 Jan 2019 11:27 CET

Company Name

MITHRA

ISIN

BE0974283153

Marché

Symbole

MITRA

Connect_2019-01-30-Estelle Phase III US-en-final.pdf
Connect_2019-01-30-Estelle Phase III US-fr-final.pdf

Source

MITHRA

Fournisseur

Accueil
+ MARCHÉS
- Amsterdam
  - Cash Products
    - Stocks
      - AEX index Stocks
      - AEX ESG Stocks
    - Indices
    - Funds
    - Bonds
    - ETFs
    - Structured products
  - Derivative products
  - Company regulated news
    - Latest
    - Archive
- Euronext Bruxelles
  - Marchés au comptant
  - Marchés dérivés
  - Company regulated news
    - Latest
    - Archive
  - Expert Market
- Euronext Dublin
- Euronext Lisbonne
  - Cash Products
  - Derivative products
  - Company regulated news
    - Latest
    - Archive
- Milan
  - Cash Products
  - Derivative products
  - IPOs
- Oslo
  - Cash Products
  - Derivatives
    - Derivative products
    - Quote Vendor Codes
  - Company regulated news
    - Latest
    - Archive
  - Financial calendars
  - Primary insiders
- Paris
  - Marchés au comptant
  - Marchés dérivés
  - Communiqués sociétés
    - Latest
    - Archive
Actions
- All Markets directories
- Company regulated news
  - Latest
  - Archive
- IPOs
  - All IPOs
- Listing sponsors
- Euronext Tech Leaders
- Family business
Indices
ETFs
- Directory
- ESG ETFs
Fonds
Obligations
- ESG Bonds
- 1.5° Bonds
- All Markets directories
  - All Markets
  - Amsterdam
  - Brussels
  - Dublin
  - Lisbon
  - Oslo
  - Milan
  - Paris
Produits Structurés
Dérivés actions & devises
Marchandises
Knowledge Centre
Ressources